Financial Performance - The company's operating revenue for Q1 2024 was ¥284,795,525.11, a decrease of 7.18% compared to ¥306,811,212.93 in the same period last year[4] - The net profit attributable to shareholders was ¥28,976,245.02, down 49.01% from ¥56,826,297.00 year-on-year[4] - The basic earnings per share fell to ¥0.1834, a decline of 49.00% from ¥0.3596 in the same period last year[4] - Net profit for Q1 2024 was CNY 27,182,330.95, down 51.7% compared to CNY 56,230,385.30 in Q1 2023[27] - Total operating revenue for Q1 2024 was CNY 284,795,525.11, a decrease of 7.2% from CNY 306,811,212.93 in the same period last year[26] Cash Flow - The net cash flow from operating activities decreased by 34.65% to ¥58,399,019.66, compared to ¥89,360,198.07 in the previous year[4] - Cash inflow from operating activities totaled CNY 306,059,803.59, a decrease from CNY 325,923,079.64 in Q1 2023[30] - Total cash outflow from operating activities amounted to ¥247,660,783.93, up from ¥236,562,881.57 in the previous year, indicating a 5% increase[31] - The net cash flow from operating activities for Q1 2024 was ¥58,399,019.66, a decrease of 34.7% compared to ¥89,360,198.07 in Q1 2023[31] - The net cash flow from investing activities was -¥25,303,495.08, an improvement from -¥35,728,765.14 in the same period last year[31] - The net increase in cash and cash equivalents was -¥9,336,131.26, contrasting with an increase of ¥41,483,058.64 in Q1 2023[31] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,459,975,233.46, a decrease of 0.96% from ¥2,483,695,372.45 at the end of the previous year[4] - Current assets totaled CNY 1,764,461,469.23, down from CNY 1,783,393,385.22, indicating a decline of approximately 1.5%[23] - The company's total liabilities included accounts payable of CNY 74,047,803.95, up from CNY 59,226,782.99, indicating an increase of approximately 25%[23] - The total liabilities decreased to CNY 391,427,011.78 from CNY 411,355,038.30 year-over-year[24] - The total non-current assets were CNY 695,513,764.23, slightly down from CNY 700,301,987.23, reflecting a decrease of about 0.4%[23] Expenses - Total operating costs increased to CNY 246,017,043.14, up 6.5% from CNY 230,913,455.07 year-over-year[26] - Research and development expenses amounted to CNY 2,428,194.82, indicating ongoing investment in innovation[27] - Sales expenses increased to CNY 39,004,361.40, up from CNY 33,760,100.39 year-over-year[27] - Management expenses rose to CNY 48,914,804.77, compared to CNY 40,569,614.33 in the same period last year[27] Other Financial Metrics - The company reported a significant increase in construction in progress, which rose by 50.17% due to ongoing hospital expansion projects[8] - The company experienced a 38.58% increase in contract liabilities, attributed to higher prepayments for hospitalization and optical services[8] - Other income increased by 44.10% to ¥1,380,300, primarily due to increased government subsidies received during the reporting period[11] - The company’s investment income decreased due to a lack of new financial product purchases in the current period[12] - The company’s net profit margin was significantly impacted by increased marketing and R&D expenditures alongside declining revenues[13] Equity - Total equity attributable to shareholders of the parent company was CNY 2,073,315,638.61, slightly down from CNY 2,075,313,837.01 in the previous year[24] - The company’s total equity position remains stable, with no significant changes reported in the equity structure during the quarter[23] Cash Management - Cash and cash equivalents decreased to CNY 1,579,145,799.13 from CNY 1,588,531,430.39, reflecting a reduction of about 0.6%[22] - Cash outflow for employee payments was ¥130,335,062.45, compared to ¥103,421,250.25 in Q1 2023, reflecting a 26% increase[31] - Cash outflow for fixed asset purchases was ¥25,303,495.08, up from ¥19,798,245.14, representing a 28% increase[31] - Cash outflow from financing activities totaled ¥42,431,864.20, significantly higher than ¥12,199,255.59 in Q1 2023, marking a 248% increase[31] Audit and Accounting Standards - The company did not undergo an audit for the Q1 2024 report[33] - The company is implementing new accounting standards starting from 2024[32]
何氏眼科(301103) - 2024 Q1 - 季度财报